Clinical Significance of Dihydropyrimidine Dehydrogenase in Adjuvant 5-Fluorouracil Liver Perfusion Chemotherapy for Pancreatic Cancer
Authors:
- 1 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 240 (5) , 840-844
Abstract
Objective: To clarify the relationship between intratumoral dihydropyrimidine dehydrogenase (DPD) expression and response to 5-fluorouracil (5-FU) liver perfusion chemotherapy (LPC) in pancreatic cancer patients, we evaluated DPD expression immunohistochemically in resected pancreatic cancer tissues. Summary Background Data: Pancreatic cancer is considered a disease with a poor prognosis even if aggressive resection is performed. One of the main causes of death is hepatic metastasis soon after surgery. As a treatment, we have assessed adjuvant LPC via the portal vein using 5-FU just after pancreatectomy for advanced pancreatic cancer since 1994. However, the results remain unsatisfying. Methods: Sixty-eight resected specimens were obtained from patients with pancreatic cancer from 1988 to 2000. Formalin-fixed paraffin-embedded tissues were immunostained with polyclonal anti-DPD antibody. The relation between intratumoral DPD expression and the prognoses of pancreatic cancer patients was investigated statistically. Results: Of the 68 tumors studied, 27 carcinomas (39.7%) were DPD(+), and 41 (60.3%) were DPD(−). In the DPD(+) group, there was no significant difference between the LPC(+) and LPC(−) subgroups, whereas in the DPD(−) group the LPC(+) subgroup showed a significantly higher survival rate than the LPC(−) subgroup. Moreover, in the LPC(+) group, overall survival in the DPD(−) subgroup was significantly better than in the DPD(+) subgroup. Conclusions: An immunohistochemical evaluation of intratumoral DPD expression might be useful in predicting responsiveness to 5-FU-based chemotherapy in pancreatic cancer patients. In the DPD(−) group, liver perfusion chemotherapy using 5-FU via the portal vein is effective adjuvant therapy for pancreatic cancer once pancreatectomy has been performed.Keywords
This publication has 29 references indexed in Scilit:
- Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.International Journal of Oncology, 2000
- Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐FluorouracilJapanese Journal of Cancer Research, 2000
- Recurrence after resection for ductal adenocarcinoma of the pancreasWorld Journal of Surgery, 1997
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitationsWorld Journal of Surgery, 1995
- Detection of Hepatic Micrometastasis in Pancreatic Adenocarcinoma Patients by Two‐stage Polymerase Chain Reaction/Restriction Fragment Length Polymorphism AnalysisJapanese Journal of Cancer Research, 1995
- Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreasThe American Journal of Surgery, 1994
- A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracilEuropean Journal of Cancer, 1994
- Patterns of failure after curative resection of pancreatic carcinomaCancer, 1990
- Thymidylate synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyuridylateBiochemical and Biophysical Research Communications, 1972